Akums Drugs and Pharmaceuticals Balance Sheet Annual
BSE: 544222 | NSE: AKUMS | ISIN: INE09XN01023 | Sector: Biotechnology & Drugs| Fiscal Period | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Period End Date | Mar 26 | Mar 25 | Mar 24 | Mar 23 |
| Total Liabilities Shareholders' Equity | 5,446.97 | 4,113.44 | 3,516.37 | 3,266.53 |
| Accumulated Depreciation Total | -917.81 | -783.69 | -646.97 | -539.37 |
| Cash Equivalents | 331.91 | 18.69 | 62.14 | 0.00 |
| Other Liabilities Total | 926.54 | 70.14 | 1,426.97 | 1,061.91 |
| Accrued Expenses | 69.66 | 48.35 | 48.76 | 37.07 |
| Common Stock Total | 30.62 | 30.62 | 28.61 | 28.61 |
| Other Equity Total | 0.00 | - | - | - |
| Other Current Assets Total | 4.22 | 2.24 | 6.71 | 50.39 |
| Prepaid Expenses | 18.84 | 16.46 | 12.71 | 9.10 |
| Total Assets | 5,446.97 | 4,113.44 | 3,516.37 | 3,266.53 |
| Current Portof LT Debt/ Capital Leases | 80.59 | 7.23 | 51.33 | 41.17 |
| Additional Paid- In Capital | 1,094.18 | 1,083.97 | 127.17 | 127.17 |
| Cash | 54.09 | 82.50 | 48.92 | 51.61 |
| Total Equity | 3,313.35 | 3,047.01 | 709.50 | 717.19 |
| Long Term Investments | 1.27 | 3.59 | 3.79 | 7.84 |
| Retained Earnings( Accumulated Deficit) | 2,188.55 | 1,932.43 | 553.72 | 561.41 |
| Total Common Shares Outstanding | 15.31 | 15.31 | 15.74 | 15.74 |
| Property/ Plant/ Equipment Total- Gross | 2,542.73 | 2,333.49 | 2,024.20 | 1,731.88 |
| Tangible Book Valueper Share Common Eq | 215.87 | 198.34 | 44.51 | 45.06 |
| Goodwill Net | 2.06 | 2.06 | 2.06 | 2.06 |
| Total Liabilities | 2,133.62 | 1,066.43 | 2,806.87 | 2,549.34 |
| Total Debt | 157.43 | 88.21 | 565.23 | 622.87 |
| Short Term Investments | 1,295.05 | 480.76 | 176.77 | 98.89 |
| Cashand Short Term Investments | 1,681.05 | 581.95 | 287.82 | 150.50 |
| Total Receivables Net | 1,100.03 | 993.04 | 983.10 | 959.72 |
| Notes Payable/ Short Term Debt | 0.00 | 13.66 | 367.70 | 391.33 |
| Deferred Income Tax | 17.71 | 18.62 | 12.15 | 25.30 |
| Accounts Receivable- Trade Net | 796.56 | 770.30 | 833.81 | 845.09 |
| Property/ Plant/ Equipment Total- Net | 1,624.92 | 1,549.79 | 1,377.23 | 1,192.50 |
| Minority Interest | 17.77 | 16.60 | 10.99 | 6.19 |
| Total Current Liabilities | 1,094.76 | 893.75 | 1,210.55 | 1,265.57 |
| Total Inventory | 755.71 | 680.93 | 650.54 | 754.46 |
| Accounts Payable | 602.16 | 642.79 | 532.13 | 567.14 |
| Other Currentliabilities Total | 342.35 | 181.73 | 210.64 | 228.87 |
| Total Long Term Debt | 76.84 | 67.33 | 146.20 | 190.38 |
| Intangibles Net | 6.21 | 8.30 | 6.89 | 5.90 |
| Other Long Term Assets Total | 204.67 | 243.42 | 155.98 | 63.24 |
| Note Receivable- Long Term | 47.97 | 31.67 | 29.54 | 70.82 |
| period Length | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 3,559.86 | 2,274.61 | 1,940.88 | 1,924.16 |
| Capital Lease Obligations | 76.84 | 67.33 | 67.91 | 74.88 |
| Long Term Debt | - | 0.00 | 78.30 | 115.50 |
Akums Drugs and Pharmaceuticals Quick Links
Akums Drugs and Pharmaceuticals Dividend Akums Drugs and Pharmaceuticals Bonus Akums Drugs and Pharmaceuticals News Akums Drugs and Pharmaceuticals AGM Akums Drugs and Pharmaceuticals Rights Akums Drugs and Pharmaceuticals Splits Akums Drugs and Pharmaceuticals Board Meetings Akums Drugs and Pharmaceuticals Key Metrics Akums Drugs and Pharmaceuticals Shareholdings Akums Drugs and Pharmaceuticals Profit Loss Akums Drugs and Pharmaceuticals Cashflow Akums Drugs and Pharmaceuticals Q1 Results Akums Drugs and Pharmaceuticals Q2 Results Akums Drugs and Pharmaceuticals Q3 Results Akums Drugs and Pharmaceuticals Q4 Results
Equity Quick Links
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.